Precipio, Inc. · NASDAQ:PRPO
Precipio — Investor Presentation (2018)
17 slides from Precipio's investor presentation, 2018
Slide 1: Eradicating the Problem of Misdiagnosis by Harnessing Academic Expertise & Advanced Technologies
A DIAGNOSTIC PLATFORM COMPANY (NASDAQ: PRPO) Eradicating the Problem of Misdiagnosis by Harnessing Academic Expertise & Advanced Technologies Precipio, Inc.| Proprietary & Confidential
Slide 2: Executive summary
OVERVIEW Executive summary THE VISION THE PROBLEM THE SOLUTION THE BENEFIT Eradicate misdiagnosis Significant rate of A platform that harnesses Physicians, hospitals, so patients live longer misdiagnosis across academic expertise + payers and patients all and better lives numerous proprietary techno
Slide 3: Our team
ABOUT PRECIPIO Our team MANAGEMENT BOARD OF DIRECTORS SCIENTIFIC ADVISORY Ilan Danieli, Founder & CEO - experienced executive Sam Riccatelli, Chairman – Former President and CEO of Jeffrey Sklar, MD, PhD – Precipio’s Chief Scientific with startups, corporate restructuring and investment Signal Genet
Slide 4: Current providers misdiagnose up to 44% of patients
MARKET OVERVIEW Current providers misdiagnose up to 44% of patients Increasingly complex disease states are met with eroding specialization rather than increased expertise Economic pressures drive towards generalization DIAGNOSTIC INDUSTRY COSTS ~2% B U T IMPACTS ~70 ALL HEALTHCARE DECISIONS %
Slide 5: Misdiagnosis has massive downstream consequences
MARKET OVERVIEW Misdiagnosis has massive downstream consequences PHYSICIANS PAYERS PATIENTS Physicians administer incorrect Payers waste of valuable treatment Patients pay the ultimate treatments, creating adverse effects dollars applied incorrectly and incur price: increased morbidity rather than i
Slide 6: A Platform to achieve superior accuracy through academic expertise
THE SOLUTION A Platform to achieve superior accuracy through academic expertise Precipio is addressing the issue with an innovative, robust, scalable platform connecting all players: Physicians and their patients gain access to world -class academic experts & technologies Payers benefit from qua
Slide 7: Academic institutions possess underutilized expertise & technology
THE OPPORTUNITY Academic institutions possess underutilized expertise & technology Precipio capitalizes on the intellectual expertise & technologies developed within academic institutions: VOLUME OF TESTS ACCURACY LEVEL OUTSOURCED R&D Academia Academic institutions invest Academia: heavily in the
Slide 8: Combining Service + Technology to create new model
BUSINESS MODEL Combining Service + Technology to create new model Service Model Technology Model • Steady, stable business • Rapid, exponential growth • Gradual, slow growth • Cash-consuming business (R&D, commercialization etc.) • Cash-generating business • Significant risk associated with technolo
Slide 9: Two high valued-added offerings in the Cancer Diagnostics arena
INITIAL FOCUS Two high valued-added offerings in the Cancer Diagnostics arena Clinical Pathology Services ICP – Liquid Biopsy Technology • Clinical diagnostic services focused on blood cancers to • Cutting-edge liquid biopsy technology licensed from Dana oncologists, with demonstrated superior resul
Slide 10: Primary and 2nd opinion diagnoses via academic pathologists
PATHOLOGY SERVICES BUSINESS Primary and 2nd opinion diagnoses via academic pathologists Patient Biopsy processed at Laboratory results Academic Pathologist Report delivered undergoes biopsy our laboratory (TC) uploaded to cloud renders diagnosis (PC) to the physician Revenue model: Technical (TC): ~
Slide 11: Liquid biopsies have the potential to revolutionize patient care
LIQUID BIOPSIES Liquid biopsies have the potential to revolutionize patient care CURRENT CHALLENGES OF TISSUE BIOPSIES LIQUID BIOPSY SOLUTIONS • Enable non-invasive diagnostics • Tissue biopsies are invasive, costly; are done only ONCE, at using liquid samples initial diagnosis • Personalize treatme
Slide 12: Significant, growing, revolutionary field
LIQUID BIOPSY FIELD Significant, growing, revolutionary field The application of liquid biopsies in cancer diagnostics can be categorized into three areas: Liquid Biopsy Applications Application Diagnostic screening Treatment resistance Disease recurrence Identify tumor genetic Ongoing monitoring –
Slide 13: ICP is a patented, proprietary reagent added to any genetic platform
ICP BUSINESS MODEL ICP is a patented, proprietary reagent added to any genetic platform Specimens prepared ICP added to front Enriched DNA Genetic mutations Clinical action for analysis end process increases sensitivity detected taken Revenue model: Product: Application-specific kits (monitoring/r
Slide 14: ICP is currently the only economically viable solution to enable this revolution
ICP TECHNOLOGY ICP is currently the only economically viable solution to enable this revolution ICP Competitive Analysis Competition ICE-COLD PCR (ICP) Diagnostic/screening + Comprehensive panels + Targeted panels only Relevant Treatment Resistance – No + Yes Application Disease Recurrence – No + Ye
Slide 15: Additional possible applications to be developed in the future
ICP FUTURE POTENTIAL APPLICATIONS Additional possible applications to be developed in the future* Prenatal Testing Companion Diagnostics • Two options currenty exist: Amniocentesis (invasive • Patients with CML (Chronic Myeloid Leukemia): procedure); or maternal blood test with ~80% – Targeted thera
Slide 16: Develop current businesses + add new products to our platform
GROWTH & SCALE Develop current businesses + add new products to our platform Clinical Pathology Services Expand portfolio of services to all types of cancer Cross-sell both clinical services and IP -based technologies to our customers, creating demand and customer pipeline Build both domestic
Slide 17: Scalable Platform - addressing massive problem - with demonstrated success
SUMMARY Scalable Platform - addressing massive problem - with demonstrated success MAJOR THE PROOF OF SIGNIFICANT VALUE PROBLEM SOLUTION CONCEPT MARKET CREATOR Lack of specialization A combination of Precipio has developed The field of Diagnostics Precipio creates value and expertise results service